IL17A and psoriasis: In contrast, a large-scale cohort study in Israel found that the use of IL-17 inhibitors in patients with psoriasis was not associated with increased risk of COVID-19 infection (adjusted HR for IL-17i vs. methotrexate: 0.91 [95% CI, 0.48–1.72]; IL-17I vs. non-systemic/non-immunomodulatory treatments: 0.92 [95% CI, 0.54–1.59]) [23].